Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Pasi A. Jänne, Dong‐Wan Kim et al.|New England Journal of Medicine|2013Cited by 3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung CancerBenjamin Solomon, Fiona Blackhall, Tony Mok et al.|New England Journal of Medicine|2014Cited by 3.2k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Benjamin Solomon, Tony Mok et al.|New England Journal of Medicine|2020Cited by 1.1k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Geoffrey R. Oxnard et al.|New England Journal of Medicine|2020Cited by 835
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upLizza Hendriks, Martin Reck, Keith M. Kerr et al.|Annals of Oncology|2023Cited by 782